Alumis(NASDAQ) ALMS

Alumis helps people manage autoimmune diseases like skin rashes. It creates targeted medicines to calm the body's immune system. These treatments focus on specific proteins to reduce swelling.

The Product Pipeline

• Envudeucitinib: Tablet for skin conditions and lupus; acts as a tyrosine kinase 2 (TYK2) inhibitor, which is a type of protein blocker that stops inflammation signals.
• A-005: Medicine for brain-related swelling; designed to enter the central nervous system to treat nerve-based inflammation.
• Lonigutamab: Lab-made antibody for Thyroid Eye Disease; targets a specific cell receptor to reduce tissue growth and eye swelling.

Strategic Steps Taken

• Completed a merger with ACELYRIN in May 2025 to add new treatments to its clinical portfolio.
• Signed a development and sales agreement with Kaken Pharmaceutical in March 2025 for skin treatments in Japan.
• Raised $324.4 million through a public stock offering in January 2026 to fund operations.
• Planned a New Drug Application, which is a formal request for regulatory approval to sell a product, for envudeucitinib in late 2026.

Why it Stands Out

Alumis uses a precision data analytics platform to find specific biological targets for its drugs. Rather than using broad treatments that affect the whole body, the company builds therapies that stop the specific proteins causing disease.

A Look at the Numbers

• Revenue was $1.7 million in Q1 2026, down 90% from Q1 2025.
• Net loss reached $93.1 million in Q1 2026, which improved by 6% year-over-year.
• Operating loss narrowed by 3.1% to $98.4 million in the first quarter of 2026.
• Total cash and investments reached $569.5 million as of March 31, 2026.

Bottom Line

Alumis has evolved from a discovery-stage business to a clinical-stage organization through strategic mergers and testing. Its focus on precision medicine aims to replace broad immune treatments with more accurate, targeted options for patients.